Evolus (EOLS) Shares Outstanding (Diluted Average) (2020 - 2026)
Evolus (EOLS) reported Shares Outstanding (Diluted Average) of $65.2 million for Q1 2026, up 2.34% on a YoY basis from $63.7 million in Q1 2025, and up 1.11% quarter-over-quarter from $64.5 million in Q4 2025.
Evolus (EOLS) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Evolus has reported Shares Outstanding (Diluted Average) for 7 years, with the latest figure at $65.2 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 2.34% year-over-year to $65.2 million; the trailing twelve-month figure through Mar 2026 stood at $65.2 million (up 2.34% YoY), and the FY2025 full-year result was $64.5 million, up 3.95% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $65.2 million, up from $64.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $65.2 million in Q1 2026, with the low at $55.7 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $59.8 million across 5 years, with a median of $58.8 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) soared 35.58% — and 2023, when it gained 1.12%.
- Evolus' Shares Outstanding (Diluted Average) stood at $56.1 million in 2022, then increased by 1.52% to $56.9 million in 2023, then gained by 8.96% to $62.0 million in 2024, then climbed by 3.95% to $64.5 million in 2025, then grew by 1.11% to $65.2 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $65.2 million (Q1 2026), $64.5 million (Q4 2025), and $64.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 1.18 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 422.40 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 47.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 103.40 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 506.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 228.36 Mn |
| 10 | Evolus | 435.45 Mn | 385.65 Mn | 48.90 Mn | 65.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.19 Mn |
| Dec 31, 2025 | 64.47 Mn |
| Sep 30, 2025 | 64.32 Mn |
| Jun 30, 2025 | 64.12 Mn |
| Mar 31, 2025 | 63.70 Mn |
| Dec 31, 2024 | 62.02 Mn |
| Sep 30, 2024 | 61.56 Mn |
| Jun 30, 2024 | 60.76 Mn |
| Mar 31, 2024 | 58.80 Mn |
| Dec 31, 2023 | 56.92 Mn |
| Sep 30, 2023 | 56.81 Mn |
| Jun 30, 2023 | 56.92 Mn |
| Mar 31, 2023 | 56.48 Mn |
| Dec 31, 2022 | 56.07 Mn |
| Sep 30, 2022 | 56.18 Mn |
| Jun 30, 2022 | 55.91 Mn |
| Mar 31, 2022 | 55.73 Mn |
| Dec 31, 2021 | 49.77 Mn |
| Sep 30, 2021 | 55.01 Mn |
| Jun 30, 2021 | 44.16 Mn |